(Q36227392)

12 August 2017

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease (English)

1 reference

12 August 2017

1 reference

D Devos

1

0 references

Luc Defebvre

13

object named as

L Defebvre

1 reference

12 August 2017

P Krystkowiak

2

1 reference

12 August 2017

F Clement

3

1 reference

12 August 2017

K Dujardin

4

1 reference

12 August 2017

O Cottencin

5

1 reference

12 August 2017

N Waucquier

6

1 reference

12 August 2017

K Ajebbar

7

1 reference

12 August 2017

B Thielemans

8

1 reference

12 August 2017

M Kroumova

9

1 reference

12 August 2017

A Duhamel

10

1 reference

12 August 2017

A Destée

11

1 reference

12 August 2017

R Bordet

12

1 reference

12 August 2017

language of work or name

English

0 references

publication date

10 November 2006

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

5

1 reference

12 August 2017

470-475

1 reference

The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

The dopamine transporter and attention-deficit/hyperactivity disorder

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Excessive daytime sleepiness in parkinsonism

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Parkinson's disease: medical treatment of moderate to advanced disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Methylphenidate (OROS formulation).

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Various aspects of motor fluctuations and their management in Parkinson's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Core assessment program for intracerebral transplantations (CAPIT)

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

A New Depression Scale Designed to be Sensitive to Change

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Inter- and Intra-Rater Reliability of the Brief Psychiatric Rating Scale

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Falls efficacy as a measure of fear of falling.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

The dopamine transporter: importance in Parkinson's disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Effects of subthalamic nucleus stimulation and levodopa treatment on gait abnormalities in Parkinson disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2117830

[Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease]

22 September 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

1 reference

PubMed

12 December 2020

Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis1Published on the World Wide Web on 27 January 1998.1

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1136/JNNP.2006.100016

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

17098845

1 reference